Tag Archives: KPTI

H.C. Wainwright Reaffirms Their Buy Rating on Karyopharm Therapeutics

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $23. The company’s shares closed yesterday at $10.51. According to TipRanks.com, White is a 5-star analyst

RBC Capital Reiterates a Buy Rating on Karyopharm Therapeutics

In a report issued on November 2, Brian Abrahams from RBC Capital reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), with a price target of $15. The company’s shares closed yesterday at $11.23. According to TipRanks.com, Abrahams is a

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI), Insulet Corp (NASDAQ: PODD) and NanoString Tech (NASDAQ: NSTG)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI), Insulet Corp (NASDAQ: PODD) and NanoString Tech (NASDAQ: NSTG) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) Robert W.

RBC Capital Keeps a Buy Rating on Karyopharm Therapeutics

RBC Capital analyst Brian Abrahams reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) on October 16 and set a price target of $14. The company’s shares opened today at $11.34. According to TipRanks.com, Abrahams is a 5-star analyst with

Analysts’ Top Healthcare Picks: KPTI, WVE

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI), Wave Life Sciences (NASDAQ: WVE) and China Biologic (NASDAQ: CBPO) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) In

Karyopharm Therapeutics Received its Third Buy in a Row

After Jefferies and Robert W. Baird assigned a Buy rating to Karyopharm Therapeutics in the last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Mara Goldstein maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today